FOR IMMEDIATE RELEASE:

ORALDNA® LABS INTRODUCES TWO SALIVARY DNA TESTS TO SUPPORT DENTISTS’ FIGHT AGAINST PERIODONTAL DISEASE

Molecular DNA Tests Positioning Dental Professionals at the Forefront of Oral Medicine – Company Planning the Launch of HPV/Oral Cancer DNA Test in 2010

Nashville, TN – November 16, 2009 – OralDNA® Labs Inc. (www.OralDNA.com), leaders in advancing wellness in dentistry through salivary diagnostics, and a subsidiary of Quest Diagnostics® Incorporated (NYSE: DGX), today announced the availability of two revolutionary molecular tests to help periodontists and general dentists identify patients with and at risk for periodontal disease.

MyPerioPath® identifies the type and concentration of specific perio-pathogenic bacteria that are known to cause periodontal disease, while MyPerioID® PST® identifies an individual’s genetic susceptibility to periodontal disease. The test enables clinicians to establish which patients are at increased risk for more severe periodontal infections due to an exaggerated immune response.

Used together, the new salivary DNA diagnostic tests can help dental professionals reduce patient incidence of periodontal disease. MyPerioPath® provides early and accurate diagnosis of existing periodontal disease by identifying and measuring specific types of bacteria, while MyPerioID® PST® assesses a patient’s genetic predisposition to developing periodontal disease well before physical symptoms occur. The company has launched a national dental industry awareness and training program to support the profession’s understanding and effective use of the new tools.

According to OralDNA® Labs Inc. senior vice president and general manager Robert Walker, the company has been introducing the tests to leading dental industry practitioners during the past year.

“Leading periodontists and general dentists are already relying on the MyPerioPath® and MyPerioID® PST® salivary diagnostic tests to provide insights for enhanced patient care, and as important tools in the fight against periodontal disease. We believe these tests will not only help put dental professionals at the forefront of oral medicine, but also enable them to provide more comprehensive and accurate treatment plans for their patients.”

-more-
According to the American Dental Association, an estimated 75% of all Americans over
the age of 35 have some form of periodontal disease and research conducted during
the past 10 years has provided insight into the Perio/Systemic Connection and the link
between chronic periodontal infections and heart disease, diabetes, stroke, and some
forms of cancer.\(^3,4\)

Within the next year, OralDNA® expects to add the clinician-administered oral DNA HPV
test, OraRisk\(^{sm}\) HPV, a non-invasive, easy-to-use screening tool to identify the type(s) of
oral HPV, a mucosal viral infection that could potentially lead to oral cancer. The test will
enable the clinician to establish increased risk for oral cancer and determine appropriate
referral and monitoring conditions.

For more information, education, and training related to OralDNA®’s salivary DNA
diagnostic tests, dental professionals, including periodontists, general dentists, and
dental hygienists, should visit www.OralDNA.com/training or call (877) 577-9055.

About OralDNA® Labs Inc. (www.OralDNA.com)
OralDNA® Labs Inc., a subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), is a
specialty diagnostics company created to advance clinical testing in the dental
community. The company’s goal is to help the dental profession achieve better clinical
outcomes by providing reliable, definitive, and cost-effective clinical tests that drive the
detection and prognosis of disease at an earlier, more treatable stage, with an initial
focus on periodontal disease. OralDNA® offers two DNA-Polymerase Chain Reaction
(PCR) tests for periodontal disease diagnosis and genetic susceptibility: MyPerioPath®
detects the presence and quantity of specific bacteria associated with periodontal
disease, while MyPerioID® PST®, which is licensed through a marketing, sales, and
distribution agreement with Interleukin Genetics, provides a means of assessing an
individual’s genetic risk for periodontal disease. The company has also developed an
oral HPV test named OraRisk\(^{sm}\) HPV for use in assessing the risks associated with
certain types of oral cancer.

About Quest Diagnostics®
Quest Diagnostics® is the world’s leading provider of diagnostic testing, information, and
services that patients and clinicians need to make better healthcare decisions. The
company offers the broadest access to diagnostic testing services through its network of
laboratories and patient service centers, and provides interpretive consultation through
its extensive medical and scientific staff. Quest Diagnostics® is a pioneer in developing
innovative new diagnostic tests and advanced healthcare information technology
solutions that help improve patient care. Additional company information is available at

References:
2. Genco R, Offenbacher S, Beck J. Periodontal disease and cardiovascular disease:
epidemiology and possible mechanisms. JADA 2002;133(Suppl.):14S-22S.
3. Friedewald VE, Kornman KS, Beck JD, et al. The American Journal of Cardiology and
Journal of Periodontology editors’ consensus: periodontitis and atherosclerotic
4. Van Dyke TE. The management of inflammation in periodontal disease. J Periodontol

###